Anthony Fernandez, MD, PhD

Appointed
2011

Education & Fellowships

Residency - University of Miami Hospitals and Clinics
Dermatology
Miami, FL
2009

Internship - Loyola University Medical Center
Internal Medicine
Maywood, IL United States
2006

Medical Education - University of Illinois College of Medicine
MD
Chicago, IL
2005

Medical Education - University of Illinois at Chicago College of Medicine
Chicago, IL
2003

Professional Highlights

• Kinahan CE, Mazloom S, Fernandez, AP.  Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study.  Br J Dermatol 2015; 172(2): 428-436.
• Gonzalez E, Billings SD, Fernandez AP.  A refractory rash in a seborrheic distribution.  Lancet2015; 385: 1777.
• Kinahan CE, Mazloom S, Fernandez, AP.  Impact of smoking on response to systemic treatment in patients with psoriasis: a retrospective case-control study.  Br J Dermatol 2015; 172(2): 428-436.
• Romero-Talamás H, Aminian A, Corcelles R, Fernandez AP, Schauer PR, Brethauer S.  Psoriasis Improvement After Bariatric Surgery. Surg Obes Rela Dis 2014; 10(6): 1155-1159.
• Napekoski KM, Fernandez AP, Billings SD.  Microvenular Hemangioma: A clinicopathologic review of 13 cases.  J Cutan Pathol 2014; 41(11): 816-22
• Ko JS, Billings SD, Lanigan CP, Buehler D, Fernandez AP, Tubbs RR. Fully Automated Dual-Color Dual-Hapten Silver In-Situ Hybridization Staining for MYC Amplification: a Diagnostic Tool for Discriminating Secondary Angiosarcoma. J Cut Pathol 2014; 41: 286-292.
• Triozzi P, Fernandez AP.  The Role of the Immune Response in Merkel Cell Carcinoma.  Cancers 2013; 5: 234-254.
• Fernandez AP, Wolfson A, Ahn E, Maldonado JC, Alonso-Llamazares J.  Kasabach-Merritt phenomenon in an adult man with a Tufted Angioma arising in a Port-Wine-Stain and Hepatitis-C cirrhosis responding to electron beam radiation, bevacizumab, and prednisone.  Int J Dermatol; 2014; 53(9): 1165-1176. 
• Ko JS, Fernandez AP, Anderson KA, Burdick LM, Billings SD, Procop GW, McMahon JT, Bergfeld WF, Piliang MP.  Morphologic mimickers of Cryptococcus occurring within inflammatory infiltrates in the setting of neutrophilic dermatitis: a series of three cases highlighting clinical dilemmas associated with a novel histopathologic pitfall.  J Cut Pathol 2013; 40(1): 38-45.
• Fernandez AP, Sun Y, Tubbs R, Goldblum J, Billings SD. FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations. J Cut Pathol 2011; In press.
• Konda S, Fernandez AP, Berman B, Elgart G, Milikowski C, Alonso-Llamazares J. Toxic epidermal necrolysis in the setting of systemic lupus erythematosus. Int J Dermatol 2011; 50(10): 1270-1275.
• Fernandez AP, Miteva M, Roberts B, Rouhani P, Ricotti C, Romanelli P. Histopathologic analysis of dermal lymphatic alterations in chronic venous insufficiency ulcers using D2-40. J Am Acad Dermatol 2011, 64: 1123.e1-12.
• Fernandez AP, Hu S, Kirsner RS. Sirolimus: a potential chemopreventive agent. J Invest Dermatol 2008; 128(10): 2352.
• Fernandez AP and Kerdel FA. The Use of IVIG therapy in Dermatology. Dermatologic Therapy, vol 20, #4 July/August 2007: 288-305.
• Fernandez AP, Piliang M, Bergfeld W. The significant role of cutaneous pathology for diagnosis of systemic lupus erythematosus in the setting of chronic Hepatitis-C cirrhosis. 47th Annual American Society of Dermatopathology meeting Program, Atlanta, GA, October 2010.
• Fernandez AP, Ricotti C, Nousari CH. Increased mitotic rate of lesional histiocytes in multicentric reticulohistiocytosis is associated with underlying malignancy. 45th Annual American Society of Dermatopathology meeting Program, San Francisco, CA, October 2008; page 131.
• Fernandez AP, Ricotti C, Nousari CH. Proliferative multicentric reticulohistiocytosis associated with metastatic hepatocellular carcinoma. 45th Annual American Society of Dermatopathology meeting Program, San Francisco, CA, October 2008; page 87.
• Fernandez AP, Ricotti C, Nousari CH. The spectrum of histopathologic and immunopathologic findings in cutaneous lesions associated with dermatomyositis. 45th Annual American Society of Dermatopathology meeting Program, San Francisco, CA, October 2008; page 116.

Certifications

• Dermatology - Dermatopathology
• Dermatology

Specialty Interests

Dermatopathology, dermatomyositis, lupus, psoriasis, scleroderma, vasculitis, bullous pemphigoid, pemphigus, connective tissue diseases, cutaneous T-cell lymphoma, pyoderma gangrenosum, cutaneous ulcers, panniculitis, Sezary Syndrome

Awards & Honors

• 2015 Finance Chair, ASDP
• 2015 Caregiver Award; Cleveland Clinic
• 2014 Director of Medical Dermatology; Cleveland Clinic, 2014 to Present
• 2014 Financial Committee Chair, American Society of Dermatopathology
• 2014 Teacher of the Year, Dermatopathology; Cleveland Clinic
• 2013 Teacher of the Year, Clinical Dermatology, Cleveland Clinic
• 2009 Miami Dermatological Society Resident's Research Day-1st Place Award
• 2009 Jaime Battan Compassionate Patient Care Award, University of Miami
• 2006 Intern of the Year- Department of Internal Medicine, Loyola University
• 2005 Association of Pathology Chairs Honor Society
• 2004 Alpha Omega Alpha Honor Society
• 2001 Sigma Xi Graduate Student Research Forum, UIC - Philip L. Hawley 1st Place Award

Memberships

• Medical Dermatology Society
• Rheumatologic Dermatology Society
• Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
• American Academy of Dermatology
• The Myositis Association
• The National Lupus Foundation
• The Scleroderma Foundation
• The Vasculitis Foundation
• International Pemphigus Pemphigoid Foundation
• National Psoriasis Foundation
• American Society of Dermatopathology

See publications for Anthony Fernandez, MD, PhD.

(Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)

Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.

To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists receive or have the right to receive royalties or (iv) its physicians/ scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.

As of 4/21/2025, Dr. Fernandez has reported the financial relationships with the companies listed below. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by Cleveland Clinic. To learn more about Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.

Consulting and/or Speaking. Dr. Fernandez receives fees of $5,000 or more per year (or, in rare cases, equity or stock options) as a paid consultant, speaker or as a member of an advisory committee for the following companies:

• Bristol-Myers Squibb
• Mallinckrodt, plc
• AbbVie, Inc.
• Biogen Idec, Inc.

Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers' discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.

* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.